Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer
Hormone receptor (HR)‐positive and human epidermal growth factor receptor 2 (HER2)‐
negative breast cancer is defined by the presence of the estrogen receptor and/or the …
negative breast cancer is defined by the presence of the estrogen receptor and/or the …
Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer
Normal cells explore multiple states to survive stresses encountered during development
and self-renewal as well as environmental stresses such as starvation, DNA damage, toxins …
and self-renewal as well as environmental stresses such as starvation, DNA damage, toxins …
Overcoming endocrine resistance in breast cancer
Estrogen receptor-positive (ER+) breast cancer is the most common breast cancer subtype.
Treatment of ER+ breast cancer comprises interventions that suppress estrogen production …
Treatment of ER+ breast cancer comprises interventions that suppress estrogen production …
Therapeutic resistance to anti-oestrogen therapy in breast cancer
M Will, J Liang, C Metcalfe, S Chandarlapaty - Nature Reviews Cancer, 2023 - nature.com
The hormone receptor oestrogen receptor-α (ER) orchestrates physiological mammary
gland development, breast carcinogenesis and the progression of breast tumours into lethal …
gland development, breast carcinogenesis and the progression of breast tumours into lethal …
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial
NC Turner, B Kingston, LS Kilburn… - The Lancet …, 2020 - thelancet.com
Summary Background Circulating tumour DNA (ctDNA) testing might provide a current
assessment of the genomic profile of advanced cancer, without the need to repeat tumour …
assessment of the genomic profile of advanced cancer, without the need to repeat tumour …
Genomic characterization of metastatic breast cancers
Metastasis is the main cause of death for patients with breast cancer. Many studies have
characterized the genomic landscape of breast cancer during its early stages. However …
characterized the genomic landscape of breast cancer during its early stages. However …
Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future
The development and approval of cyclin-dependent kinase (CDK) 4 and 6 inhibitors for
hormone receptor-positive and human epidermal growth factor receptor 2 (HER2)-negative …
hormone receptor-positive and human epidermal growth factor receptor 2 (HER2)-negative …
Mechanisms of sensitivity and resistance to CDK4/6 inhibition
M Álvarez-Fernández, M Malumbres - Cancer cell, 2020 - cell.com
Inhibiting the cell-cycle kinases CDK4 and CDK6 results in significant therapeutic effect in
patients with advanced hormone-positive breast cancer. The efficacy of this strategy is …
patients with advanced hormone-positive breast cancer. The efficacy of this strategy is …
[HTML][HTML] Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond
C Marchiò, L Annaratone, A Marques, L Casorzo… - Seminars in cancer …, 2021 - Elsevier
The human epidermal growth factor receptor 2 (HER2) is a well-known negative prognostic
factor in breast cancer and a target of the monoclonal antibody trastuzumab as well as of …
factor in breast cancer and a target of the monoclonal antibody trastuzumab as well as of …
The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor–positive metastatic breast …
SA Wander, O Cohen, X Gong, GN Johnson… - Cancer discovery, 2020 - AACR
Mechanisms driving resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in
hormone receptor–positive (HR+) breast cancer have not been clearly defined. Whole …
hormone receptor–positive (HR+) breast cancer have not been clearly defined. Whole …